Table 1.
Baseline characteristics of the study population
| Placebo/placebo (n = 11) | Lefitolimod/placebo (n = 11) | Placebo/bNAb (n = 12) | Lefitolimod/bNAb (n = 12) | |
|---|---|---|---|---|
| Age (years) | 54 (45–60) | 44 (38–53) | 51 (41–54) | 48 (31–53) |
| Female sex | 2 (18) | 1 (9) | 3 (25) | 1 (8) |
| Race and ethnicity | ||||
| African European | 0 (0) | 2 (18) | 0 (0) | 0 (0) |
| White | 11 (100) | 7 (64) | 11 (92) | 11 (92) |
| More than one | 0 (0) | 2 (18) | 1 (8) | 1 (8) |
| Time since HIV-1 diagnosis (years) | 11 (4–37) | 12 (1–15) | 11 (2–29) | 8 (2–26) |
| Time from HIV-1 diagnosis to ART (years) | 0 (0–14) | 1 (0–5) | 0 (0–21) | 0 (0–7) |
| Time on ART (years) | 8 (4–23) | 9 (1–14) | 8 (2–23) | 8 (2–26) |
| HIV subtype a | ||||
| B | 8 (73) | 5 (45) | 9 (75) | 11 (92) |
| Non-B | 0 (0) | 4 (36) | 2 (17) | 1 (8) |
| Not available | 3 (27) | 2 (18) | 1 (8) | 0 (0) |
| CD4+ T cell count (cells per mm3) | 743 (708–820) | 694 (620–920) | 1,027 (808–1,240) | 832 (723–1,450) |
| HLA class I alleles a | ||||
| Risk: HLA-B*07 and HLA-B*35 | 5 (45) | 5 (45) | 3 (25) | 5 (42) |
| Protective: HLA-B*27, HLA-B*57 and HLA-B*58 | 1 (9) | 2 (18) | 2 (17) | 0 (0) |
Data are n (%) or median (range).
a Individual HIV-1 subtypes and HLA class I can be found in Supplementary Table 1.